2 citations
,
September 2025 in “International Journal of Nanomedicine” Extracellular vesicles can help treat skin issues like wounds, hair loss, aging, and inflammation.
1 citations
,
January 2026 in “International Journal of Dermatology” Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
August 2025 in “JEADV Clinical Practice” PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.
September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.
December 2023 in “International Journal of Dermatology” 2 citations
,
October 2025 in “Frontiers in Medicine” Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
October 2024 in “International Journal For Multidisciplinary Research” Wedelolactone may help treat chronic diseases due to its strong antioxidant properties.
February 2026 in “International Journal of Molecular Sciences” Extracellular vesicles show promise for medical use but face challenges in standardization and safety.
March 2026 in “Journal for ImmunoTherapy of Cancer” Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.
July 2025 in “Burns & Trauma” 3D cell spheroids can help reduce scars by delivering therapeutic vesicles.
2 citations
,
June 2025 in “Preprints.org” Targeting amphiregulin may improve treatment for fibrotic diseases and cancer.
July 2024 in “Journal of Investigative Dermatology” ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.
June 2026 in “Precision medicine and engineering.” The hydrogel dressing RD@PVA helps heal diabetic wounds by reducing stress and improving blood vessel growth.
April 2019 in “Journal of Investigative Dermatology” Y27632 increases cell growth through EGFR signaling, not ROCK1/2.
10 citations
,
November 2015 in “Experimental Dermatology” Skin RAGE levels are linked to inflammation and cell death.
4 citations
,
March 2023 in “IP International Journal of Comprehensive and Advanced Pharmacology” The new drug delivery system improves exemestane's absorption and effectiveness.
9 citations
,
July 2024 in “JAAD reviews.” Extracellular vesicles show potential in dermatology, but more research is needed for validation.
July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
26 citations
,
May 2012 in “Pharmaceutical Development and Technology” PEVs effectively deliver minoxidil through skin.
Deep eutectic solvents can replace toxic solvents in extracting useful compounds for medicines.
11 citations
,
September 2021 in “Journal of molecular endocrinology” ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.
Ayurvedic herbs may reduce side effects and improve effectiveness of cancer treatments.
75 citations
,
August 2006 in “International Journal of Pharmaceutics” The eucalyptus oil system improved skin delivery of hormones, but safety concerns remain.
25 citations
,
February 2024 in “Biomaterials” Stem cell-derived organoids can improve skin healing.
November 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Tectona grandis leaves may help treat hair loss and inflammation.
October 2025 in “Journal of the Endocrine Society” The patient was satisfied with hormone therapy, and her epilepsy remained stable.
The vitamin D receptor has many roles in the body beyond managing calcium, affecting the immune system, hair growth, muscles, fat, bone marrow, and cancer cells.
August 2024 in “Dermatology and Therapy” Vorasidenib can cause unusual hair growth.
October 2025 in “Frontiers in Toxicology” A new method effectively predicts estrogen-related health effects for early screening.
1 citations
,
May 2022 in “European Journal of Dermatology” Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.